Literature DB >> 19670299

Outcome in high risk patients with unprotected left main coronary artery stenosis treated with percutaneous coronary intervention.

Lisette Okkels Jensen1, Anne Kaltoft, Per Thayssen, Hans Henrik Tilsted, Evald Hoej Christiansen, Kirsten Vilain Mikkelsen, Michael Maeng, Knud Noerregaard Hansen, Anton Boel Villadsen, Morten Madsen, Jens Flensted Lassen, Knud Erik Pedersen, Leif Thuesen.   

Abstract

OBJECTIVE: We examined mortality, risk of myocardial infarction (MI), and target lesion revascularization (TLR) in high-risk patients with unprotected left main (LM) percutaneous coronary intervention (PCI) in Western Denmark.
BACKGROUND: PCI of left main coronary artery lesions may be an alternative to coronary artery bypass grafting in high-risk surgical patients.
METHODS: From January 2005 to May 2007, all patients who had unprotected LM PCI with stent implantation were identified in the Western Denmark Heart Registry. The indications for PCI were: (1) ST segment elevation MI (STEMI), (2) non-STEMI (NSTEMI) or unstable angina, and (3) stable angina. All patients were followed up for 18 months.
RESULTS: A total of 344 patients were treated with LM PCI (STEMI: 71, NSTEMI/unstable angina: 157, and stable angina: 116). In STEMI patients, the median logistic EuroSCORE was 22.5 (interquartile range 12.5-39.5), in non-STEMI (NSTEMI)/unstable angina patients 13.8 (4.8-23.9), and in stable angina patients 4.8 (2.2-10.4). Mortality after 18 months 38.0, 18.5, and 11.2% (P < 0.001) in patients with STEMI, NSTEMI/unstable angina, and stable angina, respectively. MI after 18 months was 9.9, 6.4, and 6.0% (P = ns), respectively. Four subacute and one late definite stent thrombosis were seen. TLR occurred in 5.6, 4.5, and 6.9% (P = ns) of patients, respectively.
CONCLUSION: After PCI, patients with STEMI and LM culprit lesion have a high-mortality risk, whereas long-term outcome for patients with NSTEMI and stable angina pectoris is comparable with other high surgical risk patients with unprotected left main lesion. Further, TLR rates and risk of stent thrombosis were low. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 19670299     DOI: 10.1002/ccd.22205

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

1.  High-risk diabetic patients with unprotected left main coronary artery disease: characteristics and medium-term outcomes of percutaneous revascularization with drug-eluting stents.

Authors:  Jose F Díaz Fernández; Carlos Sánchez González; Manuel Jiménez Navarro; Juan C Fernández Guerrero; Antonio Gómez Menchero; Juan H Alonso Briales; Rosa María Cardenal Piris; Juan Herrador; Manuel Guzmán Herrera; Jose M Hernández García
Journal:  Tex Heart Inst J       Date:  2011

2.  Existing data sources for clinical epidemiology: The Western Denmark Heart Registry.

Authors:  Morten Schmidt; Michael Maeng; Carl-Johan Jakobsen; Morten Madsen; Leif Thuesen; Per Hostrup Nielsen; Hans Erik Bøtker; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

3.  Therapeutic effect of interventional therapy for unprotected left main coronary artery lesions in aged patients.

Authors:  Zhong-Hai Wei; Jie Song; Lian Wang; Jing-Mei Zhang; Wei Huang; Biao Xu
Journal:  J Geriatr Cardiol       Date:  2015-11       Impact factor: 3.327

4.  Temporal Trends and Site Variation in High-Risk Coronary Intervention and the Use of Mechanical Circulatory Support: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking (CART) Program.

Authors:  Rory S Bricker; Thomas J Glorioso; Omar Jawaid; Mary E Plomondon; Javier A Valle; Ehrin J Armstrong; Stephen W Waldo
Journal:  J Am Heart Assoc       Date:  2019-12-07       Impact factor: 5.501

5.  Cardiogenic shock due to left main related myocardial infarction: is revascularization enough?

Authors:  Francisco Galván-Román; Elena Puerto; Roberto Martín-Asenjo; Albert Ariza-Solé
Journal:  J Geriatr Cardiol       Date:  2022-02-28       Impact factor: 3.327

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.